{"disease":{"id":"lupus-erythematosus-cutaneous","name":"lupus erythematosus cutaneous"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03840928","title":"PatientSpot Formerly Known as ArthritisPower","phase":"","overall_status":"UNKNOWN","enrollment_count":40000,"lead_sponsor_name":"Global Healthy Living Foundation","has_results":false},{"nct_id":"NCT06927219","title":"Research Accelerated by You Lupus Registry","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Lupus Foundation of America","has_results":false},{"nct_id":"NCT03276923","title":"Maternal Autoimmune Disease Research Alliance (MADRA) Registry","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Duke University","has_results":false},{"nct_id":"NCT05531565","title":"A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":450,"lead_sponsor_name":"Biogen","has_results":false},{"nct_id":"NCT06044337","title":"A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus","phase":"PHASE3","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":322,"lead_sponsor_name":"Biogen","has_results":false},{"nct_id":"NCT02847598","title":"Study to Evaluate BIIB059 (Litifilimab) in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":264,"lead_sponsor_name":"Biogen","has_results":true},{"nct_id":"NCT07355218","title":"A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":202,"lead_sponsor_name":"EMD Serono Research & Development Institute, Inc.","has_results":false},{"nct_id":"NCT07332481","title":"A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":202,"lead_sponsor_name":"EMD Serono Research & Development Institute, Inc.","has_results":false},{"nct_id":"NCT03122431","title":"Relevance of Monitoring Blood and Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":93,"lead_sponsor_name":"University of Sao Paulo General Hospital","has_results":true},{"nct_id":"NCT06925542","title":"A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"CRISPR Therapeutics","has_results":false},{"nct_id":"NCT04857034","title":"A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":74,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT07408908","title":"Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic (PK/PD) Profile of ACT100 in Healthy Participants..","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":48,"lead_sponsor_name":"Xiamen Amoytop Biotech Co., Ltd.","has_results":false},{"nct_id":"NCT06875960","title":"A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":35,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT07306585","title":"The Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HC022 Injection in Subjects With SLE/CLE","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":32,"lead_sponsor_name":"HC Biopharma Inc.","has_results":false},{"nct_id":"NCT03817424","title":"A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":31,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT04647708","title":"Study of M5049 in CLE and SLE Participants","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","has_results":false},{"nct_id":"NCT02656082","title":"Targeted Therapy Using Intradermal Injection of Etanercept for Remission Induction in Discoid Lupus Erythematosus","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"University of Leeds","has_results":false},{"nct_id":"NCT01559155","title":"Role of Proteasomes in a Dermatological Autoimmune Disease: Bullous Pemphigoid","phase":"","overall_status":"TERMINATED","enrollment_count":14,"lead_sponsor_name":"Centre Hospitalier Universitaire de Nīmes","has_results":false},{"nct_id":"NCT04493541","title":"A Study to Assess the Safety and Drug Levels of BMS-986256 in Participants With Active Cutaneous Lupus Erythematosus","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":13,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT02927457","title":"Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of GSK2646264 in Cutaneous Lupus Erythematosus Subjects","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":11,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT05879718","title":"A Study to Learn About the Study Medicine (PF-06823859) in Adults With Active CLE or SLE With Skin Symptoms.","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":8,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT02428309","title":"Autologous Polyclonal Tregs for Lupus","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":true},{"nct_id":"NCT04707924","title":"Efficacy of Fractional Er:YAG Laser in Lupus Erythematosus Scars","phase":"NA","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Insel Gruppe AG, University Hospital Bern","has_results":false}],"total":23},"guidelines":[],"source":"Drug Landscape verified database"}